相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort
Edmond Chiche et al.
BLOOD ADVANCES (2021)
Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia
Kishan K. Patel et al.
BLOOD ADVANCES (2021)
CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial
Jeffrey E Lancet et al.
Lancet Haematology (2021)
Cost-effectiveness analysis of oral azacitidine maintenance therapy in acute myeloid leukemia
Jan Philipp Bewersdorf et al.
BLOOD ADVANCES (2021)
Healthcare resource utilization in a phase 3 study of CPX-351 in patients with newly diagnosed high-risk/secondary acute myeloid leukemia
Kathleen F. Villa et al.
JOURNAL OF MEDICAL ECONOMICS (2020)
CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program
Fabio Guolo et al.
BLOOD CANCER JOURNAL (2020)
Health state utilities associated with treatment options for acute myeloid leukemia (AML)
Louis S. Matza et al.
JOURNAL OF MEDICAL ECONOMICS (2019)
CPX-351 As Induction Chemotherapy Yields Similar Responses and Survival Outcomes in Younger Patients (<60 Years Old) Compared to Older Patients (≥60 Years Old) with Acute Myeloid Leukemia
Dasom Lee et al.
BLOOD (2019)
Medicare Cost at End of Life
Ian Duncan et al.
AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE (2019)
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
Jeffrey E. Lancet et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States
Jill A. Bell et al.
LEUKEMIA RESEARCH (2018)
Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populations
Eytan M. Stein et al.
JOURNAL OF MEDICAL ECONOMICS (2018)
Systematic review of health state utility values for acute myeloid leukemia
Anna Forsythe et al.
CLINICOECONOMICS AND OUTCOMES RESEARCH (2018)
Acute myeloid leukemia: a retrospective claims analysis of resource utilization and expenditures for newly diagnosed patients from first-line induction to remission and relapse
William Irish et al.
CURRENT MEDICAL RESEARCH AND OPINION (2017)
Economic burden associated with acute myeloid leukemia treatment
Amer M. Zeidan et al.
EXPERT REVIEW OF HEMATOLOGY (2016)
Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses Second Panel on Cost-Effectiveness in Health and Medicine
Gillian D. Sanders et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves
Patricia Guyot et al.
BMC MEDICAL RESEARCH METHODOLOGY (2012)
分享论文
